

Learner Notification

City of Hope- Department of Clinical Cancer Genomics
2024-2025 Veteran's Administration Cancer Genomics in Practice
January 15, 2024 – January 14, 2025
Live Online / Enduring

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. If you need MOC credit, you also need to pass a posttest with a score of at least 80%. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and City of Hope- Department of Clinical Cancer Genomics (COH). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity / enduring material for a maximum of **38.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) MOC Credit



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **38.0** Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC ONLY: You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives - After Attending This Program You Should Be Able To

1. Acquire a foundation of knowledge about germline and somatic testing in oncology practice.
2. Develop proficiency and confidence to order and interpret tumor and germline tests.
3. Identify, refer and/or manage patients with hereditary predisposition to cancer.
4. Increase awareness and use of cancer genomics resources in the VA system.
5. Identify patients who may be eligible for targeted cancer therapeutics.
6. Support your clinical practice with evidence-based genetic cancer risk assessment skills

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Kathleen	Blazer	NA
Kelly	Bolton	Servier:Research Grant Overall Principal Investigator
Alexandra	Capasso	NA

Anuja	Chitre	NA
Jane	Churpek	UpToDate, Inc:Other
Julie	Culver	NA
Madeline	Currey	NA
Sandra	Dreike	NA
Tobias	Else	MERCK:Scientific/Medical Advisory Board Member
Carol	Fabian	NA
Judy	Garber	AMBRY GENETICS:Research Grant Site Principal Investigator,ASTRAZENECA:Research Grant Overall Principal Investigator,INVITAE GENETICS:Research Grant Site Principal Investigator,MYRIAD GENETICS:Research Grant Site Principal Investigator,HELIX GENETICS:Consultant,KONICA MINOLTA:Consultant
Lauren	Gima	NA
Veda	Giri	NA
Stacy	Gray, MD, AM	Harvard Medical School:Consultant
Heather	Hampel	Genome Medical:Scientific/Medical Advisory Board Member,Natera:Scientific/Medical Advisory Board Member,GI OnDemand:Consultant,GI OnDemand:Other,Genome Medical:Private Stock Shareholder,Carelon:Consultant,23andMe:Consultant
Karen	Hurley	NA
Gregory	Idos	NA
Junne	Kamihara	PanTher Therapeutics:Other,ROME Therapeutics:Other,TellBio, Inc.:Other,Sonata Therapeutics:Other,Tekla Capital:Other,ImproveBio, Inc.:Other,Moderna:Other,Ikena Oncology:Other,Sanofi:Other,ACD-Biotechnne:Other,AVA LifeScience GmbH:Other,Incyte Pharmaceuticals:Other
Jesse	Kasten	NA
Cathryn	Koptiuch	Invitae Genetics:Public Stock Shareholder
Sonia	Kupfer	NA
Allison	Kurian	NA
Phyllis	Leung	NA
Lisa	Madlensky	VieCure:Scientific/Medical Advisory Board Member
Rachelle	Manookian	NA
Luke	McCorkel	NA
Carolyn	Menendez	NA
Bruce	Montgomery	AstraZeneca:Research Grant Overall Principal Investigator,Janssen:Research Grant Site Principal Investigator,Beigene:Research Grant Site Principal Investigator,Astellas:Research Grant Site Principal Investigator
Bitu	Nehoray	NA
Wai	Park	NA
Colin	Pritchard	NA
Padma	Rajagopal	NA
Christina	Rybak	Natera:Employee,Natera:Public Stock Shareholder
Marvin	Rydberg	NA
Tracy	Sandstrom	NA
Christine	Serway	None:Other
Susan	Shehayeb	NA
Brian	Shuch	NA
Elise	Sobotka	NA
Ilana	Solomon	NA
Dev	Tanna	NA
Kaila	Wilson	NA
Elyssa	Zukin	NA